Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients

• Status: Recruiting
• Trial end date: 2021-07-30
• Target enrollment: 0
• Participant gender: All

Summary

Bortezomib considered the standard of care for treating multiple myeloma patients, we aimed to assess the safety and efficacy of newly approved drug (Alvocade ®) in Iraq, in newly diagnosed patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Al-Rasheed University College
• Collaborator: Baghdad Medical City
• Treatments: Bortezomib; Cyclophosphamide; Dexamethasone; Lenalidomide

Criteria

Inclusion Criteria:

• Newly diagnosis Multiple myeloma with CRAB (C: hypercalcemia, R: renal impairment, A:

anemia, and B: bone lesions)

• Age above 18 years old

Exclusion Criteria:

• Age below 18 years

• Smoldering MM